PRODUCTION OF MEDICAL PREPARATIONS FOR PARENTERAL FEEDING
Operator/initiator: TBC
Stage: Requires development and approval of predesign and design documentation
Dates: Feasibility study development period: Q2 2023. Execution period: 2026
Investment amount: Expected project cost: 147 million US dollars
INNOVATIVE RESEARCH AND PRODUCTION PHARMACEUTICAL CLUSTER TASHKENT PHARMA PARK (PHASE 1)
Operator/initiator: Pharmaceutical Industry Development Agency of the Republic of Uzbekistan
Location: Tashkent region, Zangiatinsky district, Uzbekistan
Stage: July 2021 – the main parameters of the feasibility study were set
Dates: Commissioning is expected in November 2024
Investment amount: 130,2 million US dollars
The project is developed to incentivise integrated development of the pharmaceutical industry in the Republic, including through expansion of product portfolio of medical preparations, R&D, and personnel training in accordance with international educative standards.
The project is financed through EDCG funds Eximbank of Korea, UFRD, support and development of the pharmaceutical industry and direct foreign investment. The modular structure of the cluster with a total area of 50 ha implies establishment of industrial, academic, R&D, clinical and pre-clinical sectors.
On the territory of the cluster there will be production sites to produce innovative medical devices and equipment, multi-functional research university and its components, R&D centres, public expertise centre for pharmaceutical products, a datacentre, and other required infrastructure.
PRODUCTION OF GENETICENGINEERING PREPARATIONS BASED ON HIGH-TECH BIOPHARMACEUTICALS
Operator/initiator: GOR Investment (UK)
Location: Tashkent region, Uzbekistan
Stage: Requires development and approval of predesign and design documentation
Dates: Feasibility study development period: Q2 2023.
Execution period: 2024
Investment amount: Expected project cost: 120 million US dollars
PRODUCTION OF SUBSTANCES AND MEDICAL PREPARATIONS IN THE FORM OF PILLS, CAPSULES, INJECTIONS (3 PHASES)
Operator/initiator: Cadila Pharmaceuticals Uzbekistan
Location: Andizhan region, Uzbekistan
Dates: Commissioning:
phase 1 – November 2023;
phase 2 – October 2024;
phase 3 – November 2024
Investment amount: 50 million US dollars
The Indian Cadila Pharmaceuticals Ltd. concluded an investment agreement with the Ministry of Investment and Foreign Trade of Uzbekistan on establishment of a pharmaceutical plants in the free economic zone named Andizhan-farm.
It is planned to attract direct foreign investment in 2020‑2025 valued at $50m with at least $10m to be allocated in 2020‑2021 to develop phase 1 of the project; to generate 400 new job opportunities; establishment of a modern system for pharmaceuticals production and quality management in line with international standards.
30 items of drugs and medical devices will be registered on an expedited basis with no fee charging for registration certificate.
PRODUCTION OF PHARMACEUTICALS IN THE FORM OF INJECTIONS AND INFUSIONS
Operator/initiator: Pharmaceutical company for the injectables production (under construction) ROMPHARM NS
Location: Tashkent, Uzbekistan
Stage: Construction
Dates: Commissioning dates are not yet known
Investment amount: 20 million US dollars
The investment project is being developed jointly with the Romanian pharmaceutical company for the construction of a new plant for the injectables production. Stage 1 of construction is ongoing. Contractors have not yet been selected.
PRODUCTION AND FRACTIONATION OF IMMUNE CELLS OF ANTI-CANCER AND STERILE MEDICAL PREPARATIONS, BLOOD PLASMA TREATMENT (PHASE 1)
Operator/initiator: Rafarma Pharmaceuticals (USA)
Location: Innovative R&D pharmaceutical cluster Tashkent Pharma Park
Stage: Requires development and approval of predesign and design documentation
Dates: Feasibility study development period: Q1 2023. Execution period: 2024
Investment amount: Expected project cost: 45 million US dollars
